One hit wonders rarely pan out! http://beta.fool.com/rghanley/2013/03/27/the-danger-of-the-one-hit-wonder/28262/?source=eogyholnk0000001
that only makes sense, I've heard PDUFA date is July 29. 2013. Also heard decision may be made by May 5...........I was e-mailed by a recruiter, responded and haven't heard back, so this may take some time.
Great point. Mediocre data, big pharma sales leaders...only newbies at big pharma oncology will jump at this dog…or the S/A losers…
Adcom in May, Pdufa in July... I wouldn't take this on without a contingent offer based on drug approval. Would be bad to make a jump only to be laid off!!
True. Great opportunity for those who have been recently fired or layed off, or those trying to break into oncology. For those of us with success and experience in oncology, this company is not even a consideration. Bets are this company will not exist in 12-18 months.
They will be around. Not a blockbuster but should get approved and no one really selling in kidney cancer currently. Nexavar not focusing on that indication. Crowded market, but it will be sole focus of Aveo. They're going to pay well and have stock, so might look into it.
Would you double dip and not tell your current company you are working for Aveo until the PDUFA date? Got a few weeks vacation to kill in product training? Didn't think so. So why take the risk?
Tough sell. Nexavar better after crossover comparison or before being blinded to crossover for OS. This is a dog product.
